

Nuclear Medicine

UPDATE 2023

PUSHING THE
BOUNDARIES OF
THERANOSTICS

ORGANISER BY



NUCLEAR MEDICINE SOCIETY
(SINGAPORE)



09 - 11 FEBRUARY 2023
ACADEMIA | SINGAPORE



WWW.NMSS.ORG.SG

Single Photon Emission Imaging Family

Cardiac

Digital



MyoSPECT

Get to the heart of every challenging case

General Purpose SPECT w/Planar



NM 830

Innovation with scalability for growth

Hybrid SPECT/CT



NM/CT 850

Give every SPECT the perspective of CT



NM/CT 860

The ideal balance of CT performance and clinical capability



NM/CT 870 DR

A leading light in clinical discovery



NM/CT 870 CZT

Bring theory to life with CZT

Digital

Scalability

ORGANISING COMMITTEE

ORGANISING CHAIR



PROF SEAN YAN
Singapore General Hospital
Singapore

ORGANISING ADVISOR



PROF DAVID NG
Singapore General Hospital
Singapore

SCIENTIFIC CHAIR



DR HIAN LIANG HUANG
Singapore General Hospital
Singapore

SCIENTIFIC COMMITTEE



DR BUTCH MAGSOMBOL
Singapore General Hospital
Singapore

SCIENTIFIC COMMITTEE



DR YONG QIN CHANG
Singapore Radiopharmaceuti
Singapore

SCIENTIFIC COMMITTEE



SSN SING YIEN LING
Singapore General Hospital
Singapore

SCIENTIFIC COMMITTEE & SOCIAL CHAIR



MR S SOMANESAN
Singapore General Hospital
Singapore

EXHIBITION CHAIR



MR ELIAS W ELIAS
Singapore General Hospital
Singapore

INVITED FACULTY

AUSTRALIA

Grace KONG • Sze Ting LEE • Andrew SCOTT

BELGIUM

Tim VAN DEN WYNGAERT

CHINA

Libo CHEN • Mei TIAN • Meiyun WANG • Hong ZHANG

GERMANY

Richard P. BAUM

HONG KONG

Thomas S LEUNG

INDONESIA

Eko PURNOMO

MALAYSIA

TAN Teik Hin • Chai Hong YEONG

PHILIPPINES

Patricia BAUTISTA-PENALOSA • Jefferson R. PAGSISIHAN

SOUTH KOREA

Henry BOM

TAIWAN

Ruoh-Fang YEN

UNITED KINGDOM

John BUSCOMBE • Wai Lup WONG

VIETNAM

PHAM Cam Phuong

SINGAPORE

Shawn CHEN • Lenith CHENG • Edmund CHIONG • CHUA Wei Ming • Bill CLAXTON • Anbalagan KANNIVELU • KHOR Yiu Ming • Winne LAM • LIM Hwee Yong • Kelvin LOKE • Kyin MYINT • NGAM Pei Ing • ONG Seng Chuan • Gideon OOI • Saabry OSMANY • Andrew TAN • David TAI • Charlene TANG • THAM Wei Ying • THANG Sue Ping • Aaron TONG • XIE Wan Ying • Sumbul ZAHEER • ZHANG Jing Jing

AUSTRIA

Irene VIRGOLINI

BULGARIA

Sonya SERGIEVA

CYPRUS

Savvas FRANGOS

GREECE

John KOUTSIKOS

INDIA

P Shanmuga SUNDARAM

JAPAN

Takahiro TSUCHIKAWA • Hiroshi WAKABAYASHI

MYAMAR

War War WANN MAUNG

SOUTH AFRICA

Mike SATHEKGE

SWITZERLAND

John PRIOR • Axel ROMINGER • Kuangyu SHI

THAILAND

Tanyaluck THIENTUNYAKIT

UNITED STATES

Twyla BARTEL • Michael G. STABIN • Xiankai SUN

ACKNOWLEDGEMENT

The Organising Committee of the Nuclear Medicine Update 2023 wishes to express its appreciation to the following for the strong support:

GUEST OF HONOUR

Prof. Kenneth Kwek
Chief Executive Officer, Singapore General Hospital

INVITED FACULTY

All overseas and local invited speakers, moderators and judges.

SOCIETIES, ASSOCIATIONS AND ORGANISATION

ACNM

American College of Nuclear Medicine



ACKNOWLEDGEMENT

The Organising Committee of the Nuclear Medicine Update 2023 wishes to express its appreciation to the following for the strong support:

DIAMOND SPONSOR



PLATINUM SPONSOR



GALA DINNER SPONSOR



LUNCH SYMPOSIUM SPONSORS



WORKSHOP SPONSOR



SILVER SPONSOR



OTHER SPONSORS

Coffee Break Sponsor



Exhibitor



Inserts Sponsor



PHILANTHROPIC SPONSOR





RADIATION DIVISION

INTELLIGENT SOLUTIONS FOR

NUCLEAR MEDICINE & RADIOPHARMACEUTICALS

A Nuclear Medicine Supplies and Setup

- Dose Calibration System
- Thyroid Uptake System
- Lead-Lined Laboratory Furniture
- Shielding and Storage
- Syringe and Vial Shields
- Lung Ventilation Systems and Accessories
- Contamination Monitoring System
- Radiation Monitoring System
- Phantom
- Calibration Sources
- Decay Tanks & Hot Waste Management System
- Innovative and Customization Solution

B SPECT & Therapy Radiopharmaceuticals

- Iodine-131 (oral solution and capsules)
- Iodine-131 based therapeutics
- Erbium-169, Rhenium-186, and Yttrium-90 for isotopic radiation synovectomy
- Gallium-67
- Iodine-125
- Thallium-201
- Samarium-153
- TC-99m Generator
- Lutetium-177 n.c.a.
- Actinium - 225

C SPECT Cold Kits

Kit for the preparation with Tc-99m:

- Stannous pyrophosphate
- Sestamibi
- Nanocolloid
- Bicisate
- DPD, HMDP, MDP
- DTPA
- DMSA
- Monoclonal antibody (Mab) BW 250/183
- Human albumin macroaggregates
- Phytate
- Mag3

D PET Radiopharmaceuticals

- Gallium-68 Generator
- Rubidium-82 Generator
- FDG
- FLT/F-MISO and other possibilities upon request

PET Chemistry Synthesizers

- F18-NaF/FDG/FLT/F-MISO Synthesis Modules
- C-11 Synthesis Modules
- O-15 Radiowater System
- Lu-177 Synthesis Modules
- Ga-68 Synthesis Modules

E Radiochemistry Laboratory Instruments

- Radio-TLC Imaging Scanner
- Multi-Channel Analyzer
- Radio-HPLC System
- Hot-Cell Radiochemistry Monitoring System
- PET Metabolite Detectors
- SPECT / PET Laboratory Management System Software

F Research

- Liquid Scintillation Counter
- Automatic Gamma Counter
- X-Ray/Gamma Irradiators
- Wipe Test Counters
- Micro PET /CT Animal Imaging System
- Micro SPECT /CT Animal Imaging System
- Gamma/Beta/Alpha Spectroscopy Systems
- Calibration Sources
- Alpha/Beta Counting System
- PET /MR Animal Imaging System

G Services

- Consultancy, Design and Setup of HotLab for Nuclear Medicine and PET
- Consultancy, Design and Setup of
- Calibration Laboratory
- Consultancy, Design and Setup of Cyclotron
- Local & Cross border Transportation for Radiation Materials
- Radiation leakage testing



RADIATION DIVISION

DIAGNOSTIC RADIOLOGY QUALITY ASSURANCE COMPLIANCE & PROTECTION

A Diagnostic Radiology Solutions

- Diagnostic X-Ray Quality
- Assurance Instruments
- Radiography/Fluoroscopy Phantoms and Accessories
- Film Processor Quality Assurance
- Mammography Quality Assurance
- CT Quality Assurance
- MRI Quality Assurance
- Ultrasound Quality Assurance
- Patient Skin Dosimetry
- CO₂ Insufflator
- Contrast Agent Injectors for MRI/CT
- Quantitative CT Bone Densitometry Software
- Certified MRI Compatible Infusion System
- Certified MRI Compatible Patient Monitoring System
- Radiology AI Solutions

B Companion Diagnostics

- Radiation Therapy Positioning Equipments and Localization
- Radiation Therapy Tools
 - Spirometric Motion Management System for DIBH Therapy
- Radiation Therapy Positioning Equipments and Localization
 - Immobilization Devices
 - Couch Overlays
 - Thermoplastic Mask

C Diagnostic Radiology Solutions

- Survey Meters
- Area Monitors
- Personal Dosimetry
- Lead Aprons
- Lead Shields (mobile/non-mobile)
- Radiation Protection Goggles / Glasses
- Radiation Dose Management Software

D Education and Training

- Anthropomorphic Phantoms
- Multi-Channel Analyzers

E Services

- Consultancy Services in Diagnostic Compliance
- Compliance testing Servicedation Safety
- Compliance Testing Services
- Customized Lead Shielding Fabrication

F Gastroenterology

- CO Insufflator

SOCIAL PROGRAMME

You are cordially invited to the following events:

WELCOME RECEPTION

Date: Wednesday, 08 February 2023
Time: 1800 – 2000 hrs
Venue: Ngee Ann Kongsi Auditorium Foyer, Level 1, Academia

Dress code: Smart Casual

OPENING CEREMONY

Date: Thursday, 9 February 2023
Time: 0800 – 0815 hrs
Venue: Ngee Ann Kongsi Auditorium, Level 1, Academia

All participants are to be seated by **0750 hrs for the Opening Ceremony**.

NUCLEAR MEDICINE SOCIETY (SINGAPORE) ORATION & GALA DINNER

Date: Friday, 10 February 2023
Time: 1800 – 2100 hrs
Venue: The Ballroom, Level 1, Mount Faber Peak
109 Mount Faber Rd, Singapore 099203



Dress code: Business Casual

Attending participants are to gather at **5.30pm**, at the Concourse, level 1 for the transfer to the gala dinner venue.

PROGRAMME OVERVIEW

WED, 08 FEB	THU, 09 FEB	FRI, 10 FEB		SAT, 11 FEB
	INAUGURATION	SCIENTIFIC SESSIONS 1 MSK/ INFECTION IMAGING	SCIENTIFIC SESSIONS 2 DOSIMETRY	PLENARY 7 THERANOSTICS IN ASIA
	PLENARY 1			
	PLENARY 2	SCIENTIFIC SESSIONS 3 NEURO	SCIENTIFIC SESSIONS 4 RADIOPHARMA CEUTICALS	PLENARY 8: NEUROENDOCRI NE TUMOR / RCC THERANOSTICS
	LUNCH SYMPOSIUM	LUNCH SYMPOSIUM		LUNCH SYMPOSIUM
	PLENARY 3 PROSTATE CANCER THERANOSTICS	SCIENTIFIC SESSIONS 5 TOTAL BODY PET/CT	ORAL ABSTRACT PRESENTATION	CLOSING ADDRESS & AWARD CEREMONY
PRE- CONFERENCE DOSIMETRY WORKSHOP	PLENARY 4: NOVEL THERANOSTICS	PLENARY 6 THYROID THERANOSTICS		OPTIONAL SOCIAL ACTIVITY
	PLENARY 5 PHILIPPINES PRESENTS			
WELCOME RECEPTION		NUCLEAR MEDICINE SOCIETY (SINGAPORE) ORATION DINNER		

**Symbia Pro.specta SPECT/CT
with myExam Companion**

**Modernize to
MAXIMIZE**

siemens-healthineers.com/symbiaprospecta



SIEMENS
Healthineers

Nuclear Medicine

UPDATE 2023

PUSHING THE
BOUNDARIES OF
THERANOSTICS

09 - 11 February 2023
ACADEMIA, SINGAPORE

www.nmss.org.sg

PRE-CONFERENCE: WEDNESDAY, 08 FEBRUARY 2023

1500 – 1530	Registration	Foyer, Level 1
1530 – 1715	DOSIMETRY WORKSHOP (SPONSORED BY SIRTEX)	L1-S1, Level 1
1530 – 1535	Welcome and Introduction	
1535 – 1600	Overview of Y-90 for Treatment of Liver Tumors	
1600 – 1630	Dosimetric Models for Y90	
1630 – 1645	MIM Presentation	
1645 – 1715	MIM Hands-on Session	
1800	Nuclear Medicine Update 2023 Welcome Reception	

Nuclear Medicine

UPDATE 2023

PUSHING THE
BOUNDARIES OF
THERANOSTICS

09 - 11 February 2023
ACADEMIA, SINGAPORE

www.nmss.org.sg

DAY 1: THURSDAY, 09 FEBRUARY 2023


0700 – 0800	Registration	Academia Foyer, Level 1
0800 – 0815	INAUGURATION	Auditorium, Level 1
0800 – 0805	Welcome Address A/Prof. Sean Yan, President, Nuclear Medicine Society (Singapore); Organising Chair, Nuclear Medicine Update 2023	
0805 – 0815	Opening Address by Guest of Honour Prof. Kenneth Kwek Chief Executive Officer, Singapore General Hospital	
0815 – 0945	PLENARY 1	Auditorium, Level 1
Moderator	Dr. Huang Hian Liang & A/Prof. Grace Kong	
0815 – 0845	Imaging the Tumour Microenvironment	Prof. Andrew Scott, Australia
0845 – 0915	From Molecular Imaging to Phenomic Imaging	Prof. Mei Tian, China
0915 – 0945	Importance of Theranostics Education and Training Requirements	A/Prof. Sze Ting Lee, Australia
0945 – 1015	Coffee & Tea Break / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1
1015 – 1145	PLENARY 2	Auditorium, Level 1
Moderator	Dr. Anbalagan Kannivelu & Dr. Ong Seng Chuan	
1015 – 1045	Considerations for Establishing a National Lutetium Prostate Cancer Service: From the Perspective of the National Advisor NHS England	Dr. Wai-Lup Wong, UK
1045 – 1115	Quantitative SPECT/CT: A Mature Imaging Modality for the Clinics	Prof. John Prior, Switzerland
1115 – 1145	SPECT/CT Imaging in Malignant Melanoma	Prof. Sonya Sergieva, Bulgaria
1145 – 1215	Boston Scientific Lunch / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1

DAY 1: THURSDAY, 09 FEBRUARY 2023 (continued)

1215 – 1315	LUNCH SYMPOSIUM (SPONSORED BY BOSTON SCIENTIFIC)	Auditorium, Level 1
Moderator	Dr. Aaron Tong	
1215 – 1235	Latest Dosimetry Committee Guidelines with 5 Different Clinical Scenarios Focusing on the Dosing Perspective	Dr. Thomas Leung, Hong Kong
1235 – 1255	Tumor Coverage ≠ Tumor Absorbed Dose	Dr. Kelvin Loke, Singapore
1255 – 1305	SGH Case Studies on Radiation Segmentectomy	Dr Tham Wei Ying, Singapore
1305 – 1315	Questions & Answers	
1315 – 1445	PLENARY 3: PROSTATE CANCER THERANOSTICS	Auditorium, Level 1
Moderator	Dr. Lenith Cheng & Dr. Thang Sue Ping	
1315 – 1345	PSMA-targeted Radioligand Therapy: Singapore Experience	Dr. Thang Sue Ping, Singapore
1345 – 1415	Update on 225Ac-PSMA in Prostate Cancer	Prof. Mike Sathekge, South Africa
1415 – 1445	Radiomolecular Precision Oncology (RMPO) Using Beta and Alpha Emitters for the Diagnosis and Treatment of Metastatic Prostate Cancer: An Ongoing Revolution	Prof. Richard Baum, Germany
1445 – 1515	Coffee & Tea Break / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1
1515 – 1645	PLENARY 4: NOVEL THERANOSTICS	Auditorium, Level 1
Moderator	Prof. Shawn Chen & A/Prof. Jing Jing Zhang	
1515 – 1545	Genesis and Development of FAP Targeted Therapeutics	Prof. Andrew Scott, Australia
1545 – 1615	Peptide Targeted Radiotherapy (PTRT) of Solid Tumors: 3.5 Years Clinical Experience with 177Lu-, 225Ac- and 90Y-labeled Peptides Targeting the Fibroblast Activating Protein	Prof. Richard P. Baum, Germany
1615 – 1645	RCC Theranostics	A/Prof Sze Ting Lee, Australia
1645 – 1745	PLENARY 5: PHILIPPINES PRESENTS	Auditorium, Level 1
Moderator	Dr. Butch Magsombol	
1645 – 1705	Establishing a Theranostics Center and Formulating a National Position Statement and Guide on Theranostics in a Developing Country	Dr. Patricia Bautista-Peñalosa, Philippines
1705 – 1725	SIRT in the Philippines: A Single Institution Experience	Dr. Jefferson Pagsisihan, Philippines
1725 – 1745	Preliminary Efficacy and Safety Data of PRRT in the Philippines	Dr. Patricia Bautista-Peñalosa, Philippines
End of Day 1		

Xeleris V Applications

Everything you need
to do great work



Q.Lung AI

A deep learning-based SPECT/CT lung lobe segmentation application that produces fast and reproducible lung lobe segment analysis, trachea segment masking for pulmonary embolism evaluation and a guided auto analysis of quantitative lobal and lung function.



Q.Volumetrix AI

AI-enabled quantitative software that facilitates advanced segmentation and quantitation capabilities for SPECT/CT and PET/CT data without impeding workflow for both baseline and longitudinal studies.



Dosimetry for Theranostics

Dosimetry Toolkit uses consecutive patient WB SPECT/CT and/or WB planar datasets for quantifying changes in radiopharmaceutical uptake over time and calculating residence time per organ for Radio-Isotope Therapy (RIT) treatment planning purposes



Q.Liver

A one-stop-shop for processing, quantifying and reviewing liver SPECT/CT as well as tools for calculating the therapeutic SIRT treatment doses with a user-defined formula.



EXINI Bone

Incorporates AI to display whole-body bone scan images, segmentation of skeletal regions, highlights of hotspots with locally increased uptake, calculations of the bone scan index and the option to display and analyze multiple studies simultaneously.



GE HealthCare

DAY 2: FRIDAY, 10 FEBRUARY 2023

0730 – 0800	Registration	Academia Foyer, Level 1
0800 – 0930	SCIENTIFIC SESSION 1: MSK/INFECTION IMAGING Auditorium, Level 1	SCIENTIFIC SESSION 2: DOSIMETRY L1-S4, Level 1
Moderator	Dr. Saabry Osmany & Dr. Sumbul Zaheer	Mr. S Somanesan
0800 – 0830	Imaging Hip/Knee Prosthesis & the Spine (1) Prof. Tim Van den Wyngaert, Belgium	Radiation Dosimetry for Radiopharmaceuticals Prof. Michael G. Stabin, USA
0830 – 0900	Case-Based Review of Nuclear Medicine Imaging of Infection/Inflammation Dr. Twyla Bartel, USA	Integrated Artificial Intelligence and Systems Biology for Personalised Radioligand Therapy Prof. Kuangyu Shi, Switzerland
0900 – 0930	Imaging Hip / Knee Prosthesis & the Spine (2) Prof. Tim Van den Wyngaert, Belgium	Lessons Learnt from Personalised Dosimetry in Lu-177-PSMA and Lu-177-DOTATATE Therapies Prof. Dr. Yeong Chai Hong, Malaysia
0930 – 1000	Coffee & Tea Break / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1
1000 – 1130	SCIENTIFIC SESSION 3: NEURO Auditorium, Level 1	SCIENTIFIC SESSION 4: RADIOPHARMACEUTICALS L1-S4, Level 1
Moderator	Dr. Andrew Tan & Dr. Xie Wan Ying	Dr. Chang Yong Qin & Mr. Elias Woodrow Elias
1000 – 1030	Transpathology: Molecular Imaging-based Pathology Prof. Hong Zhang, China	Theranostic Small Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release Prof. Xiankai Sun, USA
1030 – 1100	PET in Neurodegeneration – From Bench to Bedside Prof. Axel Rominger, Switzerland	Cancer Radiotheranostics Prof. Shawn Chen, Singapore
1100 – 1130	Molecular Brain Imaging-Guided Therapy in Neurodegenerative Diseases A/Prof. Tanyaluck Thientunyakit, Thailand	Cholecystkinin/Gastrin/Bombesin Theranostics Prof. Irene Virgolini, Austria
1130 – 1200	Novartis Lunch / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1

DAY 2: FRIDAY, 10 FEBRUARY 2023 (continued)

1200 – 1300	LUNCH SYMPOSIUM (SPONSORED BY NOVARTIS (SINGAPORE) PTE LTD) PSMA-TARGETED THERANOSTICS: TOWARDS CLINICAL IMPLEMENTATION IN ADVANCED PROSTATE CANCER		Auditorium, Level 1
1200 – 1205	Welcome & Introduction	A/Prof. David Ng, Singapore	
1205 – 1220	Advanced Prostate Cancer: Treatment Landscape and Future Horizons	A/Prof. Edmund Chiong, Singapore	
1220 – 1235	PSMA-targeted Theranostics and Setting Up a Treatment Centre	Dr. Winnie Lam, Singapore	
1235 – 1255	Case Study: Learnings from the Multidisciplinary Experts Panelists: A/Prof. Edmund Chiong, Dr. Winnie Lam, Prof. Irene Virgolini, Prof. Mike Sathekge		
1255 – 1300	Questions & Answers		
1300 – 1500	SCIENTIFIC SESSION 5: TOTAL BODY PET/CT Auditorium, Level 1	ORAL PRESENTATION L1-S4, Level 1	
Moderators	Dr. Ngam Pei Ing & Dr. Andrew Tan	Dr. Lenith Cheng & Dr. Gideon Ooi	
1300 – 1310		Prognostic Value of BRAF(V600E) Mutation in Papillary Thyroid Carcinoma: Initial Experience in Bangladesh Dr. Papia Akhter, Bangladesh	
1310 – 1320	Total-Body PET – Where are we today? Prof. Axel Rominger, Switzerland	Low Dose 99mTc Per technetate as Anti-inflammatory Agent in Dermatitis of BALB/c Mice Dr. Hendra Budiawan, Indonesia	
1320 – 1330		Evaluation of Translocator Protein (TSPO) Radiotracer [18F]FEPPA in Mouse Models of Acute Zika and Dengue Infection-associated Inflammation Mr. Arun Ganasarajah, Singapore	
1330 – 1340		Modern Lutetium-177 PSMA Theranostics using Single Time-Point Predictive Dosimetry Simulated by Ga-68 PSMA PET/CT Dr. Yung Hsiang Kao, Australia	
1340 – 1350	Clinical Application of 2M TB PET Prof. Wang MeiYun, China	Clinical Value of 18(F)FDG-PET-CT in the Management of Osteogenic Sarcoma - Research Study of 16 Cases Dr. Karan Peepre, India	
1350 – 1400		Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin $\alpha\beta3$ in Various Cancer Types Mr. Zhao Liang, China	

DAY 2: FRIDAY, 10 FEBRUARY 2023 (continued)

1300 – 1500	SCIENTIFIC SESSION 5: TOTAL BODY PET/CT Auditorium, Level 1	ORAL PRESENTATION L1-S4, Level 1
Moderators	Dr. Ngam Pei Ing & Dr. Andrew Tan	Dr. Lenith Cheng & Dr. Gideon Ooi
1400 – 1410		Non-invasive Treatment of Recalcitrant Keloids with Contact Brachytherapy using Phosphorus 32 Skin Patch and its Effectiveness: A Pilot Study Dr. Hari Hara Sudhan N, India
1410 – 1420	The Potential of Artificial Intelligence in Total-Body PET Prof. Kuangyu Shi, Switzerland	The Vital Role of a Speciality Nurse in Inpatient Radionuclide Treatment Ms. Amanda Ong, Singapore
1420 – 1430		Lutetium-177 Microspheres as a Promising Candidate for Selective Intra-Arterial Radionuclide Therapy (Sirt): In-Vitro and Dosimetry Studies A/Prof. Jaya Shukla, India
1430 – 1440		Nursing Roles in Nuclear Theranostics – SGH Practice of PRLT for Prostate Cancer Ms. Sing Yien Ling, Singapore
1440 – 1450	GE Presentation: Total Molecular Imaging for Theranostics Mr. Erez Levy, Israel	Norepinephrine transporter-targeted PET/CT imaging with 18F-MFBG in patients with neuroblastoma: A Prospective Study Ms. Peipei Wang, China
1450 – 1500		Predictors for Disease Free and Progression Free Survivals in Metabolic Responders and Non-Responder on Follow Up FDG PET/CT after Chemoradiation in Nasopharynx Cancer Patients Prof. Maseeh Uz Zaman, Pakistan
1500 – 1530	Coffee & Tea Break / Trade Exhibition / Poster Viewing	
		Academia Foyer, Level 1

DAY 2: FRIDAY, 10 FEBRUARY 2023 (continued)

1530 – 1700	PLENARY 6: THYROID THERANOSTICS	Auditorium, Level 1
Moderators	Dr. Kao Yung Hsiang & Dr. Khor Yiu Ming	
1530 – 1600	Treating Thyroid Cancer Patients: Different Guidelines, Different Approaches	Dr. Savvas Frangos, Cyprus
1600 – 1630	Personalised Dosimetry for Radioactive Iodine Therapy of Thyroid Cancer	Prof. Henry Bom, Korea
1630 – 1700	Targeted Therapy for Advanced Metastatic Thyroid Cancer	Prof. Libo Chen, China
1700 – 1730	The role of Nuclear Medicine in the Management of Benign Thyroid Diseases, in Theranostics Era	Dr. John Koutsikos, Greece
1730 – 1800	TRANSFER TO NMS(S) ORATION & GALA DINNER	Academia Foyer
1800 – 2200	NUCLEAR MEDICINE SOCIETY (SINGAPORE) ORATION & GALA DINNER (SPONSORED BY UNITED IMAGING HEALTH)	Mount Faber Peak
1800 – 1830	Cocktail & Speech by Dr. Jusong Xia, United Imaging Healthcare	
1830 – 1835	Welcome Address A/Prof. Sean Yan, President, Nuclear Medicine Society (Singapore)	
1835 – 1840	Citation of Prof John Buscombe Dr. Wai-Lup Wong, Lister and Mount Vernon Hospital, United Kingdom	
1840 – 1920	Theragnostics from Saul Hertz to Singapore 2023 Prof. John Buscombe, Barts Health London, United Kingdom	
1920 – 2200	Dinner	
2200	End of Day 2	

Nuclear Medicine

UPDATE 2023

PUSHING THE
BOUNDARIES OF
THERANOSTICS

09 - 11 February 2023
ACADEMIA, SINGAPORE

www.nmss.org.sg

DAY 3: SATURDAY, 11 FEBRUARY 2023


0730 – 0800	REGISTRATION	Academia Foyer, Level 1
0800 – 1000	PLENARY 7: THERANOSTICS IN ASIA	Auditorium, Level 1
Moderators	Prof. Kyin Myint / Prof. Sean Yan	
0800 – 0815	Theranostics in India Dr. P Shanmuga Sundaram, Amrita Institute of Medical Sciences, India	
0815 – 0830	Theranostic Nuclear Medicine in Indonesia Dr. Eko Purnomo, Indonesian Society of Nuclear Medicine, Indonesia	
0830 – 0845	Theranostics in Japan - Present and Future Dr. Hiroshi Wakabayashi, Japanese Society of Nuclear Medicine, Japan	
0845 – 0900	Nuclear Medicine & Theranostics in Malaysia Adj A/Prof. Tan Teik Hin, Malaysian Society of Nuclear Medicine & Molecular Imaging, Malaysia	
0900 – 0915	Current Status and Future Aspects of Theranostics in Myanmar Prof. War War Wann Maung, Myanmar Medical Association (Nuclear Medicine), Myanmar	
0915 – 0930	Theranostics in Singapore - A Patient/Patient Advocate's View Mr. Bill Claxton, Carcinoid & Neuroendocrine Tumour Society of Singapore, Singapore	
0930 – 0945	Theranostic Experience in Taiwan Prof. Ruoh-Fang Yen, Society of Nuclear Medicine, Taiwan	
0945 – 1000	The Status and Challenges in Theranostics in Vietnam Prof. Pham Cam Phuong, Vietnamese Society of Radiology and Nuclear Medicine, Vietnam	
1000 – 1030	Coffee & Tea Break / Trade Exhibition	Academia Foyer, Level 1
1030 – 1200	PLENARY 8: NEUROENDOCRINE TUMOR	Auditorium, Level 1
Moderators	Dr. Chua Wei Ming & Dr. Charlene Tang	
1030 – 1100	Disease Biomarkers, Especially Liquid Biopsy to Predict Treatment Efficacy and Recurrence in Neuroendocrine Neoplasms	Prof. Takahiro Tsuchikawa, Japan
1100 – 1130	Molecular Imaging in NET: Current Status, Special Considerations and New Developments	A/Prof. Grace Kong, Australia
1130 – 1200	177Lu-DOTE-TATE in NET: Status Quo and Special Considerations	Prof. Irene Virgolini, Austria
1200 – 1230	Novartis Lunch / Trade Exhibition / Poster Viewing	Academia Foyer, Level 1

DAY 3: SATURDAY, 11 FEBRUARY 2023

(continued)

1230 – 1330	LUNCH SYMPOSIUM (SPONSORED BY NOVARTIS (SINGAPORE) PTE LTD) <i>CHALLENGING GEP-NET CASES- LEARNING FROM THE EXPERTS</i>	Auditorium, Level 1
1230 – 1235	Welcome & Introduction	A/Prof. Sean Yan, Singapore
1235 – 1315	Case & Panel Discussion Panelists: Prof John Buscombe, Dr. Lim Hwee Yong, Prof. Takahiro Tsuchikawa	Dr David Tai, Singapore
1315 – 1330	Questions & Answers	
1330 – 1400	CLOSING ADDRESS & AWARD CEREMONY	Auditorium, Level 1
Best Oral & Best Poster Awards Presentation Dr. Huang Hian Liang, Scientific Chair, Nuclear Medicine Update 2023		
Closing Remarks A/Prof. David Ng, Vice-President, Nuclear Medicine Society (Singapore)		
1400 – 1430	Let's talk about the World Federation Dr. Savvas Frangos, President Elect 2023-2024, World Federation of Nuclear Medicine and Biology (WFNMB)	
1430	End of Day 3	

NUCLEAR MEDICINE UPDATE 2023 LEVEL 1 FLOORPLAN



INFORMATION

MEETING VENUE:

ACADEMIA

20 College Road, Singapore 169856 (located in Singapore General Hospital Campus)

REGISTRATION:

Registration fees include name badge, admission to scientific sessions, exhibition, Welcome Reception, NMS(S) Oration and Gala Dinner, all teas and lunch.

Dinner ticket for Accompanying Person to Welcome Reception & NMS(S) Oration & Gala Dinner are to be purchased separately.

ON-SITE REGISTRATION:

On-site registration will begin on Thursday, 09 February 2023, 0700 hours at the Concourse, Level 1, Academia.

REGISTRATION DESK HOURS:

Date	Thursday, 9 February	Friday, 10 February	Saturday, 11 February
Time	0700 – 1700 hrs	0730 – 1700 hrs	0730 – 1400 hrs
Venue	Academia Concourse, Level 1 Singapore General Hospital Campus 20 College Road, Singapore 169856		

ADMISSION:

Name badges should be worn at ALL times as admission to all sessions is strictly by name badge only. There will be no replacement of name badges.

LANGUAGE:

The official language of the meeting is English.

TEA BREAKS:

Daily morning, afternoon tea breaks & lunches will be provided at Ngee Ann Kongsi Auditorium Foyer, Level 1.

EXHIBITION:

Exhibition will be held from Thursday, 09 February 2023, 0800hrs to Saturday, 11 February 2023, 1400hrs at the Ngee Ann Kongsi Auditorium Foyer Level 1, Academia.

WIFI:

Complimentary wifi access is available. Please note that access may be limited at peak periods.

COVID-19 UPDATE AND VENUE REQUIREMENTS:

Mask-wearing is required at **ALL** times during the conference, as Academia is located within the premise of Singapore General Hospital (healthcare facilities).

** From 29 August 2022, mask wearing is optional in all settings **except for Hospitals***, healthcare facilities, welfare and sheltered homes for the aged and disabled, ambulances and public transportation (including bus and train). Mask-wearing is required in all premises of these facilities including at retail or F&B establishments located within the building.*

Even as mark-wearing is removed in most settings, individuals are encouraged to wear masks when in crowded places, or when visiting or interacting with vulnerable persons.

Singapore have removed all requirements for delegates to check-in to the Venue for contact tracing or to have proof of vaccination documentation requested prior to entry.

INFORMATION

MEDICAL INSURANCE:

Delegates are strongly urged to seek their own medical insurance coverage. The organiser will not be responsible for any exigencies during the meeting.

COVID-19 PRE-DEPARTURE PCR SWAB TEST:

Delegates who are required to do COVID-19 pre-departure PCR swab test prior to returning home may book your swab test with any of the following organisations:

www.travelswab.sg

www.swab.sg

minmed.sg/covid-19-pcr-swab-test

Kindly note that the organiser is not responsible for all costs related to predeparture PCR testing, on-arrival PCR testing and positive COVID-19 infection including medical care, extended hotel stays, changes in travel arrangements, and any other expenses related to COVID-19.

CERTIFICATES:

In an effort to save the earth, Certificate of Attendance and or Certificate of Presentation will be provided to all participants in PDF Format. The certificate will be sent to the email address provided during pre-registration.

To obtain a copy of your e-certificate, please:

1. Check in your attendance at the Registration Counter;
2. At the end of the conference, scan the QR Code at the back of your namebadge to evaluate the event before 17 February 2023;
3. E-Certificate will be emailed to you within 2 week upon completion of the evaluation form.

In the event if you did not receive our email, please email to the Secretariat at nmupdate@nmss.org.sg.

ORGANISING SECRETARIAT:

Enquiries can be directed to the Organising Secretariat:

Tel: (65) 9105 8697

Email: nmupdate@nmss.org.sg

POSTER LISTING

POSTER LISTING		Foyer, Level 1
P-01	Thyroid Storm Following Radioactive Iodine (RAI) Therapy in Hasan Sadikin General Hospital Bandung Dr Septi Hardina, Hasan Sadikin Hospital, Indonesia	
P-02	Relationship between Neuropsychiatric Lupus Patients' Vitamin D Status and Brain Perfusion Dr Nasreen Sultana, National Institute Of Nuclear Medicine And Allied Sciences, Bangladesh	
P-03	Diagnostic and Prognostic Value of [18F]F-DOPA PET/CT for Medullary Thyroid Cancer Prof Shuren Li, Medical University of Vienna, Austria	
P-04	Proportion of Unilateral Condylar Hyperplasia in Patients with Facial Asymmetry and Agreement of Bone Scintigraphy Techniques between SPECT and SPECT/CT Dr Yutapong Raruenrom, Faculty of Medicine, Khon Kaen University, Thailand	
P-05	Prior to Surgery, Parathyroid SPECT/CT in Patients with Hyperparathyroidism Improves Diagnostic Precision Dr Urnas Islam, National Institute of Nuclear Medicine And Allied Sciences, Bangladesh	
P-06	Renography Examination at the Department of Nuclear Medicine and Molecular Theranostics Dr. Hasan Sadikin General Hospital Period 2019-2022 Dr Miraz Hedi Kusumah, Dr. Hasan Sadikin General Hospital, Indonesia	
P-07	Association of Serum Prostate Specific Antigen Levels with Fluorine-18 Fluorocholine Positron Emission Tomography / Computed Tomography Scans to Evaluate Post-Treatment Tumor Recurrence Among Filipino Prostate Cancer Patients Dr Andrew Dominic Kalaw, Cardinal Santos Medical Center, Philippines	
P-08	Efficacy and Safety of 225Ac-Dotatate in the Treatment of Neuroendocrine Tumors with High SSTR Expression Dr Dengsai Peng, The Affiliated Hospital of Southwest Medical University, China	
P-09	Novel Radiopharmaceutical 68Ga/177Lu-DOTA-IBA: Targeted Diagnosis and Treatment of Bone Metastases Dr Qixin Wang, The Affiliated Hospital of Southwest Medical University, China	
P-10	FDG PET/CT in Patients with Ovarian Cancer and its Association with Ca125 Mr Simon Beshliev, University Institute of Positron Emission Tomography, North Macedonia	
P-11	Functional Visceral Fat Activity Evaluated by Postoperative F-18 FDG PET/CT in Rectal Cancer Patients Mr Goran Spirov, University Institute of Positron Emission Tomography, North Macedonia	
P-12	Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [177Lu]Lu-DOTAGA.(SA.FAPi)2-mediated Radiotherapy in Triple-negative Breast Cancer Mr Guangfa Bao, Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.	
P-14	Thyroid Incidentaloma Incidence Rate from FDG PET/CT in MRCCC Siloam Hospital Dr Ryan Yudistiro, MRCCC Siloam Hospital and School of Medicine Universitas Pelita Harapan, Indonesia	
P-15	The Role of FDG PET/CT for Chemotherapy Response Evaluation in Breast Cancer Dr Ryan Yudistiro, MRCCC Siloam Hospital and School of Medicine Universitas Pelita Harapan, Indonesia	
P-16	The Potential Role of Dopamine Transporter Imaging in the Diagnosis of Online Game Addiction Dr Ryan Yudistiro, MRCCC Siloam Hospital and School of Medicine Universitas Pelita Harapan, Indonesia	
P-17	Association of Hemodynamic Changes with the Scan Parameters of a Dipyrindamole Induced Stress Myocardial Perfusion Scan with Tc-99m Sestamibi in Patients with Suspected Coronary Artery Disease Dr Noel Christi C. Macapagal, Philippine Heart Center, Philippines	

POSTER LISTING

POSTER LISTING		Foyer, Level 1
P-18	The Association of Beta-Blocker Use and Bone Mineral Density: A Meta-Analysis Dr Mary Amie Gelina Dumatol, Philippine Heart Center, Philippines	
P-19	Role of Hepatobiliary Scintigraphy in Assessing the Feasibility of Surgical Separation in a Set of Omphalophagus Conjoined Twins Dr Aditi Khurana, All India Institute of Medical Sciences, India	
P-20	Adjunctive Role of Dual Time Point Imaging in Evaluating Bone Lesions with Increased 18F-PSMA-1007 Uptake Dr Patrick Earl Fernando, Chinese General Hospital and Medical Center, Philippines	
P-21	Sonological Pseudo-gestational Sac Sign in Children and Positive 99mTc Meckel's Scan Prof Jasmine Ara Haque, Institute Of Nuclear Medicine & Allied Sciences (INMAS), DMCH Campus, Bangladesh	
P-22	High Grade Salivary Duct Carcinoma with Perineural Spread into Cerebello Pontine Angle, Mimicking as Vestibular Schwannoma Diagnosed on PET/CT - Case Report with Follow Up Dr Alok Dixit, Rajiv Gandhi Cancer Institute and Research Centre, India	
P-23	More than Meets the Eye: FDG PET-CT in Rare Gynaecological Pathologies - Case Series and Pictorial Review Dr Ahmad Zaid Zainal, Kuala Lumpur General Hospital, Malaysia	
P-24	Primary Ewing Sarcoma in Kidney and Role of F-18 FDG PETCT Scan: A Rare Case Report Dr Papia Akhter, National Institute of Nuclear Medicine & Allied Sciences, BAEC, Bangladesh	
P-25	F-18 FDG PET Neuroimaging: The Initial Experience in Single Institute of Bangladesh Dr Tapati Mandal, National Institute of Nuclear Medicine and Allied Sciences, Bangladesh	
P-26	Experience with F-18 FDG PET-CT in the Evaluation of Prostate Cancer: Single Institute (NINMAS) Perspective Dr Pupree Mutsuddy, National Institute of Nuclear Medicine and Allied Sciences, Bangladesh	
P-28	Utility of Bone Scintigraphy in Mandibular Condylar hyperplasia Dr Sanjith L.S, All India Institute of Medical Sciences, India	
P-29	Radionuclide Therapy Wards - From Radiation Safety to Patient Centric Care - A Paradigm Shift Dr Sumit Garg, All India Institute of Medical Sciences, India	
P-30	Renal Scarring on DMSA Scintigraphy in Children with History of Urinary Tract Infection: Contemporary Review of Potential Risk Factors and Scan Findings Dr Ahmad Zaid Zainal, Kuala Lumpur General Hospital, Malaysia	
P-31	Comparison of Serum Creatinine-based Estimated Glomerular Filtration Rate Equations to Measured GFR in Paediatric Nephrotic Syndrome Patients Dr Vijay Singh, Sanjay Gandhi Post Graduate institute of Medical Sciences (SGPGIMS), India	
P-32	Plummer's Patient with Distant Metastasis Carcinoma Thyroid: A Case Report Dr Bayu Aji Maulana, Hasan Sadikin General Hospital, Indonesia	
P-33	Metabolic Superscan on F-18 FDG PET/CT in a Patient with Secondary Hyperparathyroidism Dr Mohd Fazrin Mohd Rohani, Hospital Kuala Lumpur, Malaysia	
P-35	Radiation Safety Considerations of Patients Undergoing Hemodialysis after Lu-177 PSMA-617 Treatment – A Case Report Dr Yu-Yi Huang, Foo-Foundation Sun Yat-Sen Cancer Center, Taiwan	
P-36	Nicotinic Acid Administration and its Effect on Myocardial Glucose Uptake in a Known Case of Non-Diabetic Coronary Artery Disease Patient During FDG Cardiac PET Viability Assessment Dr Afroza Akhter, Institute of Nuclear Medicine and Allied Sciences, DMCH Campus, BAEC, Bangladesh	

iodine capsules

i-131

Technical Specifications



■ Qualitative and quantitative composition:

Single hard capsule contains sodium iodide (^{131}I) in the radioactivity range [37-5500 MBq]. Iodine-131 is obtained by neutron irradiation of tellurium in a nuclear reactor or by extraction from uranium fission products. Iodine-131 has a half-life of 8.02 days. It decays to stable xenon-131, by emission of gamma radiations of 365 keV (81.7%), 637 keV (7.2%) and 284 keV (6.1%) and beta radiation of maximal energy of 606 keV.

■ Excipients:

Sodium carbonate, sodium hydrogen carbonate, disodium hydrophosphate dehydrate, sodium thiosulphate pentahydrate, hard gelatin capsule.

■ Indications:

This product is used in the treatment of:

- thyroid nodular goitre, hyperthyroidism in the Graves-Basedow's disease, autonomic nodule and the toxic multinodular goitre. It is used for the thyroid residue ablation after surgery of differentiated thyroid tumours and in the treatment of iodine-accumulating metastases.

■ Posology and method of administration:

Sodium iodide Na^{131}I POLATOM, capsules for therapeutic use is a medicinal product with varying radioactivity, for oral administration. The recommended therapeutic dose is a matter for clinical judgement. This dose should be established individually for each patient.

(for detailed information see SmPC)

■ Calibration:

7 days

■ Radionuclidic purity:

≥ 99.9%

■ Radiochemical purity:

≥ 95%

■ Expiration:

21 days from the production date

■ Storage:

at temperature below 25°C

Technetium 99m generator Tc-99m

Technical Specifications

Content

Mother nuclide : Sodium Molybdate ($\text{Na}^{99}\text{MoO}_4$)
5-50 GBq/ Generator (Mo-99 radioactivity at calibration date)

Daughter nuclide: (^{99m}Tc) Sodium Pertechnetate ($\text{Na}^{99m}\text{TcO}_4$) (derived from $^{99}\text{Mo}/^{99m}\text{Tc}$ generator system)

Description

MON.TEK $^{99}\text{Mo}/^{99m}\text{Tc}$ generator contains fission Molybdenum-99 (^{99}Mo) absorbed by aluminium oxide (Al_2O_3) in a glass column, Technetium-99m (^{99m}Tc) formed by the decay of ^{99}Mo , is a radioactive isotope having a half life of 6.02 hours. After eluting by 0.9 % NaCl solution, ^{99m}Tc sodium pertechnetate solution which is isotonic, colorless, clear, sterile and suitable for I.V. injection is obtained. ^{99m}Tc sodium pertechnetate solution can be administered to the patients directly or used for labeling the kits.

Calibration Activities

5, 10, 15, 20, 25, 30, 35, 40, 45, 50 GBq
(Given values are for ^{99}Mo activity on calibration date)

Production Days

Thursday and Saturday

Calibration Days

Next Thursday (8 a.m.) after production or other days depending on request

Shelf Life

Generator : 21 days from the date of production
Eluate : 12 hours after elution time

Storage

Generator: At room temperature below 25 °C in lead shield (Do not freeze)

Eluate: At room temperature below 25 °C protected from light in lead shield

Packaging

Generator set

- 1 unit $^{99}\text{Mo}/^{99m}\text{Tc}$ radionuclide generator in the special package
- 5 vials of 10mL and 5 vials of 5mL sterile 0.9% NaCl solution in the box
- 2x5 units of sterile evacuated vials in the box
- 10 units of elution label for vial and 10 units of label for lead shield
- 10 units of swab with alcohol of 70% isopropyl
- Patient Information Leaflet

Disposal of Waste Materials

Any unused product or waste material should be disposed of in accordance with local requirements.



Lutetium n.c.a Lu-177



Element	Lutetium
Nuclide	177 Lu
Half-life	6,65 Days
Decay Mode	Beta Decay $E_{\text{max}} = 0,498 \text{ MeV}$ The most prominent gamma photon has an energy of 0.208 MeV.
Chemical Form	LuCl_3
Solvent	0,05 M HCL pH:1.0 - 2.0
Activity Concentration	>37 GBq/ml
Packaging	Inner package" 3 mL v-vial type I glass vial, closed with 20 mm bromobutyl stopper and aluminum flip off cap or 10 mL Type I glass vial, closed with 13 mm bromobutyl stopper and aluminum cap.

CONTACT DETAILS



We strive to provide a superior customer experience with the right product and flawless after sales services.

Address

67 Ayer Rajah Crescent,
#02-10/17, Singapore 139950

Phone Number

Tel: +(65) 6778 3655
Fax: +(65) 6777 7169

Email Address

sales@quantumsg.com

POSTER LISTING

POSTER LISTING		Foyer, Level 1
P-37	Role of Low Dose Radioiodine Therapy in Graves' Disease with History of Antithyroid Drug Induced (ATD) Adverse Effects Dr Shaila Sharmin, Institute of Nuclear Medicine and Allied Sciences, (INMAS), DMCH Campus, Bangladesh	
P-38	Correlation between Concentration of I-131 Radioactivity and Remnant Thyroid Volume in Ablation of Well-Differentiated Thyroid Carcinoma (DTC) Post-Total Thyroidectomy (TT) Ms Wulan Apriliani, Padjadjaran University, Indonesia	
P-39	Entrepreneurship in Theranostics - Giving a New Face to Nuclear Medicine in Asia Dr Anupam Gauba, Clearmedi Healthcare, India	
P-40	First Strike Personalized Predictive Radioiodine Prescription for Inoperable Metastatic Differentiated Thyroid Cancer Dr Yung Hsiang Kao, The Royal Melbourne Hospital, Australia	
P-41	Towards Non-invasive Cell Tracking of Cell Therapies by SPECT Imaging Dr Sven Hans Petersen, Duke-NUS, Singapore	
P-42	Comparison of [18F]FDG and [18F]FEPPA Tracer Uptake in a Mouse Model of Zika Disease Dr Carla Bianca Victorio, Duke-NUS Medical School, Singapore	
P-43	Analyses of Inflammatory Biomarker in Radioiodine Refractory Thyroid Carcinoma Patients Ms Priska Gusti Wulandari, Padjadjaran University, Indonesia	
P-47	Diagnostic Yield of 68GA Prostate-specific Membrane Antigen PET/CT-guided Robotic - Arm Assisted Transgluteal Prostatic Biopsy: An Experience from a Tertiary Care Centre in North India Dr Lokeshwaran M K, Sanjay Gandhi Post Graduate Institute of Medical Sciences, India	
P-49	Relevance of High Anti Thyroglobulin Antibody Level in Follow up Differentiated Thyroid Cancer Patients – A Single Institutional Retrospective Study Dr Awiral Saxena, Amrita Institute of Medical Sciences, India	
P-50	Role of 18F-FDG PET/CT in Differentiated Thyroid Carcinoma Patients with Tennis Syndrome Dr Rawnak Afrin, Bangladesh Atomic Energy Commission, Bangladesh	
P-52	The Role of Maximum Standardised Uptake Value of 18F-PSMA -1007 PET/CT in Primary Tumor Lesion of Prostate Cancer Dr Ryan Yudistiro, MRCCC Siloam Hospital And School Of Medicine Universitas Pelita Harapan, Indonesia	
P-53	Importance of 18(F) Fluoro-D-Oxyglucose Imaging in the Evaluation of Response to Treatment of Lung Cancer Prof Karan Peepre, Mahatma Gandhi Medical College, Hospital & University of Medical Sciences & Technology, India	
P-54	18F-FDG PET/CT Manifestations of Desmoplastic Small Round Cell Tumor in a Young Asian Male Dr Juncheng Huang, National University Hospital, Singapore	
P-55	Correlation SUV Max of 18F-PSMA-1007 PET/CT with Serum PSA Levels in Patients Prostate CA Dr Esther Panjaitan, MRCCC Siloam Hospital Semanggi, Indonesia	
P-56	Prognostic Strength of Imaging Based Parameters and Tumor Marker on Progression Free Survival in Pancreatic Cancer Patients by Using Baseline 18FDG PET/CT for Staging A/Prof Nosheen Fatima, Aga Khan University Karachi, Pakistan	

POSTER LISTING

POSTER LISTING		Foyer, Level 1
P-57	Efficacy of 18F-Fluorodeoxyglucose PET/CT and Cardiac MRI in the Diagnosis of Cardiac Sarcoidosis – A Cross Sectional Study Dr Bhargavi Jois KS, Manipal Hospitals, India	
P-58	Standardisation of Sentinel Lymph Node (SLN) Imaging, Biopsy in Early Cervix Cancer and Correlation of Scintigraphic Uptake Patterns with Histology Dr Padma S, Amrita Institute of Medical Sciences, India	
P-59	Outcome of Radioiodine Therapy in Combination with Lenvatinib for Advanced Follicular Thyroid Cancer with Brain and Adrenal Metastasis: A Case Report Dr Ayu Rosemeilia Dewi, Dharmais Cancer Hospital, Indonesia	
P-60	FAP-Targeted Radiopeptide Therapy using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in Diverse Advanced Solid Tumors: First-in-Humans Results A/Prof Jingjing Zhang, National University of Singapore, Singapore	
P-63	Diagnosis of Postoperative Lymph Node Metastasis of Thyroid Cancer Based on 18F-FDG PET/CT Radiomics Mr Xin Fan, Clinical Imaging Research Centre, National University of Singapore, Singapore	
P-64	Beyond the Bones: Extra-osseous Findings in Technetium-99m Methylene Diphosphonate Bone Scintigraphy Dr Ethany Lim, National University Hospital, Singapore	
P-65	Iodine-124 Dosimetry for Radioactive Iodine Therapy in the Treatment of Paediatric Thyroid Cancers Dr Cherie Ng, Singapore General Hospital, Singapore	

Connecting Every Step in Molecular Medicine

A Vision for Molecular Medicine.

DISCOVERY



for development of **targeted** tracers and therapy

DIAGNOSIS




with **breakthrough** PET and SPECT imaging solutions

TREATMENT



using **predictive** and advanced monitoring tools



We are focused on core challenges

At GE Healthcare we believe we can uniquely help connect the teams, data, and decisions in every step from discovery to diagnosis to treatment with intelligent efficient innovations that will ultimately help you deliver precise, personalized care. This is our vision.

There is so much data available across molecular imaging today. There are so many connection opportunities and loops to close. That's where we see significant opportunity. And we believe we're in a unique position to fulfill this vision because we are the only vendor with pharmaceutical diagnostics, cyclotrons, chemistry synthesis, PET/CT, SPECT/CT, advanced digital solutions and pharma partnerships to cover the breadth of steps from discovery to treatment.

Please contact your local GE Healthcare representative to learn more or visit <https://www.gehealthcare.com.sg/>

